HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 84.4%

Neg 0% Neu 84.4% Pos 0%

HC Wainwright & Co. analyst Sara Nik reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $3 price target.